Dysphagia Symptom Severity and Quality of Life

Overview

The aim of the study is to investigate the relationship between dysphagia symptom severity and quality of life of the patients with neurogenic dysphagia.

Full Title of Study: “The Relationship Between Dysphagia Symptom Severity and Quality of Life”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: September 8, 2017

Detailed Description

The dysphagia related quality of life and perceived dysphagia symptom severity by patients will be used as a complementary information on oropharyngeal dysphagia. Thus, the aim of the study is to investigate the relationship between dysphagia symptom severity and quality of life of the patients with neurogenic dysphagia.

Interventions

  • Other: Dysphagia evaluation
    • Dysphagia evaluation is performed in a clinical setting by an eating assessment tool. Swallowing related quality of life is also assessed.

Arms, Groups and Cohorts

  • Neurogenic dysphagia
    • Patients with neurogenic dysphagia who will willing to participate in the study, being over the age of 18, normal cognitive function ([24 points according to the Mini Mental State Examination), suffering from dysphagia at least one month, and having clinically stable neurological disease will be included. Dysphagia evaluation will be performed.

Clinical Trial Outcome Measures

Primary Measures

  • Dysphagia symptom severity
    • Time Frame: 1 month
    • Dysphagia symptom severity will be determined by an eating assessment tool.

Secondary Measures

  • Quality of life assessment
    • Time Frame: 1 month
    • Swallowing related quality of life will be determined by an dysphagia specific quality of life instrument called Swallow Quality of Life.

Participating in This Clinical Trial

Inclusion Criteria

  • Willing to participate in the study – Being over the age of 20 – Normal cognitive function – Suffering from dysphagia at least one month Exclusion Criteria:

  • Being under the age of 20 and above 65 years. – Abnormal cognitive function – Clinically unstable neurological disease

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: 65 Years

Investigator Details

  • Lead Sponsor
    • Hacettepe University
  • Provider of Information About this Clinical Study
    • Principal Investigator: SELEN SEREL ARSLAN, Principal Investigator – Hacettepe University
  • Overall Official(s)
    • SELEN SEREL ARSLAN, Principal Investigator, Hacettepe University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.